Elyxium Wealth LLC Invests $1.71 Million in Zoetis Inc. $ZTS

Key Points

• Elyxium Wealth initiated a $1.71 million position in Zoetis during the second quarter by purchasing 23,829 shares. Institutional investors collectively own approximately 92.8% of the company.
• Zoetis shares have fallen sharply, opening at $73.64 and trading near their 52-week low of $71.45, while analysts maintain a consensus “Hold” rating with an average price target of $109.62.
• The company slightly exceeded quarterly EPS expectations at $1.87, though revenue declined 0.2% year over year to $2.47 billion. Zoetis also announced a quarterly dividend of $0.53 per share, representing a 2.9% annualized yield.

Elyxium Wealth LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 23,829 shares of the company's stock, valued at approximately $1,712,000.

Several other large investors have also recently bought and sold shares of the business. Louisiana State Employees Retirement System purchased a new position in shares of Zoetis in the 1st quarter valued at about $2,542,000. Deutsche Bank AG raised its position in shares of Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company's stock worth $699,331,000 after acquiring an additional 891,921 shares in the last quarter. Pincus Capital Management LP purchased a new stake in Zoetis during the fourth quarter worth approximately $2,109,000. Highbridge Capital Management LLC purchased a new stake in Zoetis during the fourth quarter worth approximately $7,004,000. Finally, Pacer Advisors Inc. boosted its holdings in Zoetis by 16.7% in the first quarter. Pacer Advisors Inc. now owns 165,570 shares of the company's stock valued at $19,572,000 after purchasing an additional 23,687 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on ZTS shares. Weiss Ratings lowered shares of Zoetis from a "sell (d+)" rating to a "sell (d)" rating in a research note on Friday, June 12th. JPMorgan Chase & Co. reduced their price objective on shares of Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. TD Cowen lowered their target price on shares of Zoetis from $150.00 to $104.00 and set a "buy" rating for the company in a report on Tuesday, June 30th. Wall Street Zen downgraded shares of Zoetis from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. Finally, Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of "Hold" and an average target price of $109.62.

Zoetis Stock Down 2.9%

Shares of NYSE ZTS opened at $73.64 on Friday. The business has a 50-day moving average price of $76.30 and a 200 day moving average price of $99.01. The stock has a market cap of $30.43 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 1.31 and a beta of 0.74. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 52-week low of $71.45 and a 52-week high of $160.48.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the previous year, the company posted $1.76 earnings per share. The firm's revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis's dividend payout ratio (DPR) is 34.93%.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source